How will the GW pharma deal affect the industry?
This week we welcome back Oliver Zugel, CEO and Founder of Foliumed – international producers of pharmaceutical grade cannabis and extracts in Columbia.
Together, we explore the recent acquisition of GW Pharma by Jazz Pharmaceuticals, how CBD, medical cannabis, and pharmaceutical cannabis will differentiate themselves from each other, and how this will impact the cannabis industry going forwards.
→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e101
Oliver Zugel is the founder and CEO of Foliumed, a medical cannabis producer with operations in Germany and Colombia. Foliumed focuses on non-smokable, pharmaceutical product forms which permit precise dosing. Its ingredients are sourced from its organic farm in the Colombian highlands, and processed in a German EU-GMP certified facility.
2021 is the year columbian product will become more well known within the major medical cannabis marketplace 03:00
GW is ‘quite a big fish to swallow’ for the Irish company 05:00
Medical cannabis companies operate in a very different business model than GW’ 07:35
The time has come for medical cannabis companies to start thinking about how they compete 09:55
‘The medical cannabis industry isn’t about curing cancer. It’s about improving the life and wellbeing of an ageing population’ 12:30
Follow Oliver on LinkedIn: https://www.linkedin.com/in/oliverzugel/
Foliumed’s Website: www.foliumed.com
EPISODE #76 Standardisation and Medical Cannabis with Oliver Zugel, CEO at Foliumed :